Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,522
archived clinical trials in
Chronic Pain

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Winter Park, FL
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Winter Park, FL
Click here to add this to my saved trials
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Newnan, GA
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Newnan, GA
Click here to add this to my saved trials
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated:  3/23/2018
mi
from
Woodlawn, IL
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated: 3/23/2018
mi
from
Woodlawn, IL
Click here to add this to my saved trials
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Ashland, KY
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Ashland, KY
Click here to add this to my saved trials
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Bossier City, LA
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Bossier City, LA
Click here to add this to my saved trials
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
New York, NY
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Laredo, TX
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Laredo, TX
Click here to add this to my saved trials
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Lacey, WA
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Lacey, WA
Click here to add this to my saved trials
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated:  3/23/2018
mi
from
Parkville,
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Status: Enrolling
Updated: 3/23/2018
mi
from
Parkville,
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Glendale, CA
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Santa Rosa, CA
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Clearwater, FL
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Holiday, FL
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Holiday, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Miami, FL
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Miami, FL
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Stuart, FL
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Stuart, FL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Marietta, GA
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Newnan, GA
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Newnan, GA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Stockbridge, GA
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Gurnee, IL
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Gurnee, IL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Ashland, KY
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Ashland, KY
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Shreveport, LA
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Missoula, MT
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Berlin, NJ
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Berlin, NJ
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
New York, NY
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
New York, NY
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Cleveland, OH
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Lacey, WA
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Lacey, WA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Mount Vernon, IL
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Mount Vernon, IL
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
Clinical Research Facility
mi
from
Bossier City, LA
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
Clinical Research Facility
mi
from
Bossier City, LA
Click here to add this to my saved trials
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated:  3/23/2018
mi
from
Vratsa,
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy
Status: Enrolling
Updated: 3/23/2018
mi
from
Vratsa,
Click here to add this to my saved trials
Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain
Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain
Status: Enrolling
Updated:  3/27/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain
Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain
Status: Enrolling
Updated: 3/27/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain
GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain
Status: Enrolling
Updated:  3/27/2018
Boston Children's Hospital at Waltham
mi
from
Waltham, MA
GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain
GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain
Status: Enrolling
Updated: 3/27/2018
Boston Children's Hospital at Waltham
mi
from
Waltham, MA
Click here to add this to my saved trials
Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection
Scrambler Therapy for the Treatment of Chronic Zoster Pain
Status: Enrolling
Updated:  4/2/2018
The Mayo Clinic
mi
from
Rochester, MN
Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection
Scrambler Therapy for the Treatment of Chronic Zoster Pain
Status: Enrolling
Updated: 4/2/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center
mi
from
Burbank, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Mercy Cancer Center at Mercy San Juan Medical Center
mi
from
Carmichael, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
mi
from
Pomona, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
mi
from
Pomona, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Radiation Oncology Center - Roseville
mi
from
Roseville, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Radiation Oncology Center - Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Radiological Associates of Sacramento Medical Group, Incorporated
mi
from
Sacramento, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
General Robert Huyser Cancer Center at David Grant Medical Center
mi
from
Travis Air Force Base, CA
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
General Robert Huyser Cancer Center at David Grant Medical Center
mi
from
Travis Air Force Base, CA
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Integrated Community Oncology Network
mi
from
Jacksonville Beach, FL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Integrated Community Oncology Network
mi
from
Jacksonville Beach, FL
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Baptist Cancer Institute - Jacksonville
mi
from
Jacksonville, FL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Baptist Cancer Institute - Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Integrated Community Oncology Network at Southside Cancer Center
mi
from
Jacksonville, FL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Integrated Community Oncology Network at Southside Cancer Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Baptist Medical Center South
mi
from
Jacksonville, FL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Baptist Medical Center South
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Miami Cancer Center at Mercy Hospital
mi
from
Miami, FL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Miami Cancer Center at Mercy Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated:  4/3/2018
Integrated Community Oncology Network - Orange Park
mi
from
Orange Park, FL
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer
Status: Enrolling
Updated: 4/3/2018
Integrated Community Oncology Network - Orange Park
mi
from
Orange Park, FL
Click here to add this to my saved trials